Company: BIAF
Filing Date: 2025-05-05
Form Type: S-1/A
Source: 0001641172-25-008629
Chunk: 3

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-05
Form: S-1/A
Chunk 3
---
000 shares (the “Certificate of Amendment”) and the date of stockholder approval of the Anti-Dilution Adjustment (collectively, the “Warrant Stockholder Approval”). The May 2025 Warrants will expire on the five-year anniversary of the later of the date that the Company files a Current Report on Form 8-K giving public notice of the Warrant Stockholder Approval (the “Stockholder Approval Notice Date”) and the effective date of the filing of the Certificate of Amendment. The terms of the May 2025 Warrants will include (i) a one-time thirty percent (30%) increase in the number of shares of Common Stock issuable upon exercise of the May 2025 Warrants if a reverse stock split is effected prior to the expiration of the May 2025 Warrants (the Reverse Stock Split Adjustment) and (ii) subject to Warrant Stockholder Approval, a decrease of the exercise price of the May 2025 Warrants, if in a subsequent offering of our securities the price paid for Common Stock, the exercise price of any options or warrants or the conversion price of any convertible securities issued in such subsequent offering is less than the exercise price immediately prior to such subsequent offering, to an exercise price that is equal to the lowest of the price paid for Common Stock, the exercise price of any options or warrants or the conversion price of any convertible securities issued in such subsequent offering (subject to a floor of $0.10 per share) and an increase in the number of shares of our Common Stock underlying the May 2025 Warrants upon such exercise price reset so that the reset exercise price multiplied by the increased number of shares equals the aggregate proceeds that would have resulted from the full exercise of the May 2025 Warrants immediately prior to the reset (the “Anti-Dilution Adjustment”). We have agreed not to consummate a subsequent offering of our securities at a price less than the exercise price of the May 2025 Warrants immediately prior to such subsequent offering until the earlier of (i) eight months from the closing date of this offering and (ii) later of: (a) the filing of a registration statement registering certain shares of Common Stock issuable as a result of an Anti-Dilution Adjustment (as further described under “Description of the Securities We Are Offering:” (b) the Stockholder Approval Notice Date; and (c) the effective date of the filingof the Certificate of Amendment . Based on an assumed initial exercise price of $0.5489 per share (equal